Cargando…
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
The poor efficacy of the in vivo anti-tumor immune response has been partially attributed to ineffective T-cell responses mounted against the tumor. Fas-FasL-dependent activation-induced cell death (AICD) of T cells is believed to be a major contributor to compromised anti-tumor immunity. The molecu...
Autores principales: | Cao, K, Wang, G, Li, W, Zhang, L, Wang, R, Huang, Y, Du, L, Jiang, J, Wu, C, He, X, Roberts, A I, Li, F, Rabson, A B, Wang, Y, Shi, Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672172/ https://www.ncbi.nlm.nih.gov/pubmed/25745993 http://dx.doi.org/10.1038/onc.2015.46 |
Ejemplares similares
-
Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020) -
Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012) -
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo
por: Zhu, Q-y, et al.
Publicado: (2011) -
Enhancing the anti-angiogenic action of histone deacetylase inhibitors
por: Kuljaca, Selena, et al.
Publicado: (2007) -
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)